Prolactin (PRL) has been implicated in numerous physiological and developmental processes. The mouse PRL gene was disrupted by homologous recombination. The mutation caused infertility in female mice, but did not prevent female mice from manifesting spontaneous maternal behaviors. PRL-deficient males were fertile and produced offspring with normal Mendelian gender and genotype ratios when they were mated with heterozygous females. Mammary glands of mutant female mice developed a normal ductal tree, but the ducts failed to develop lobular decorations, which is a characteristic of the normal virgin adult mammary gland. The potential effect of PRL gene disruption on antigenindependent primary hematopoiesis was assessed. The results of this analysis indicated that myelopoiesis and primary lymphopoiesis were unaltered in the mutant mice. Consistent with these observations in PRL mutant mice, PRL failed to correct the bone marrow B cell deficiency of Snell dwarf mice. These results argue that PRL does not play any indispensable role in primary lymphocyte development and homeostasis, or in myeloid differentiation. The PRL -/-mouse model provides a new research tool with which to resolve a variety of questions regarding the involvement of both endocrine and paracrine sources of PRL in reproduction, lactogenesis, tumorigenesis and immunoregulation.
Introduction
Prolactin (PRL) is closely associated with the stimulation of lactogenesis in mammals, but its secretion in nonmammalian species, and the multiple effects caused by administration of exogenous PRL (Nicoll and Bern, 1972) have led to suggestions that PRL may play important 6926 © Oxford University Press roles in systems other than the mammary gland. Recent discoveries have reinforced the notion that PRL may be fundamental to the development of the reproductive (Cooke, 1995) and hematopoietic (Hooghe-Peters and Hooghe, 1995; Koojiman et al., 1996) systems.
The fact that the PRL receptor is expressed in cells in the testis, prostate gland, seminal vesicles and ovary (Nicoll and Bern, 1972; Cooke, 1995) is consistent with a role for the hormone in reproduction. Similarly, the PRL receptor has been detected on up to 95% of bone marrow cells and thymocytes (Dardenne et al., 1991; O'Neal et al., 1991; Gagnerault et al., 1993; Touraine et al., 1994) , suggesting a potential role in hematopoiesis. The PRL receptor is a member of the type I cytokine receptor superfamily, which includes numerous hematopoietic growth factor receptors Horseman and Yu-Lee, 1994) . However, despite reports that PRL can potentiate effector function of lymphoid and myeloid cells during secondary immune responses (Gala, 1991; Matera et al., 1991; Kelley et al., 1992; Sabharwal et al., 1992; Murphy et al., 1993; Hooghe-Peters and Hooghe, 1995; Warwick et al., 1995; Koojiman et al., 1996) , its involvement in the primary, antigen-independent development and homeostasis of these populations is not resolved.
Our current understanding of the physiology and pathobiology of PRL is based on administration of exogenous hormones to animals or cell cultures, and ablation of pituitary function by surgery, drugs or spontaneous genetic mutations that suppress pituitary PRL secretion. PRL is synthesized in many tissues other than the pituitary gland (Ben-Jonathan et al., 1996) . Pituitary ablation cannot remove potentially important local sources of PRL in some tissues. Consequently, many long-standing controversies regarding the role of PRL in key developmental and physiological processes have remained unresolved.
To circumvent various limitations in our understanding of PRL actions, a strain of mice with a targeted disruption of the PRL gene was generated and analyzed. The results of these analyses demonstrate that PRL is required for normal reproduction and mammary gland development in adult females; but PRL is not required for somatic growth, male reproduction, spontaneous maternal behavior, or primary differentiation or homeostatic maintenance of the blood cells.
Results

Generation of PRL-deficient mice
The PRL gene was mutated by a targeted insertion of a neomycin resistance gene (PGK-neo) into the region encoding the second α helix of the PRL protein ( Figure  1A ). Targeting was confirmed by genomic Southern blotting using enzyme cuts that were both 5Ј (BpmI) and 3Ј (HindIII) of the targeting site ( Figure 1B ). PCR amplification of genomic DNA yielded the predicted 420 and 930 bp fragments from the normal and targeted gene ( Figure 1B ). Pituitary mRNA was assayed by reverse transcriptase-PCR to confirm the loss of the PRL gene product at the mRNA level. Amplification of the 5Ј portion of the PRL mRNA (encoded by exons 1-3) yielded an expected 276 bp product in ϩ/ϩ, ϩ/-and -/-mice. Primers for the 3Ј portion of the mRNA (encoded by exons 4 and 5) yielded the expected 312 bp product in ϩ/ϩ and ϩ/-mice, and no product in the -/-mice. These results are consistent with the prediction that the mice should express a 3Ј-truncated PRL transcript as a consequence of the PGK-neo insertion.
Western blotting of pituitary gland extracts was used to assess the status of PRL gene expression at the protein level (Figure 2 ). Purified mouse PRL migrated as a 25 kDa monomer band with a larger (50 kDa) band that presumably represents a PRL dimer. A band identical to 25 kDa PRL was present in extracts from male and female ϩ/ϩ mice. Heterozygous mice synthesized predominantly the 25 kDa Fig. 2 . Western blot analysis of pituitary proteins. Pituitary extracts (10 μg) were immunoblotted as described in Materials and methods. Molecular weight markers are depicted at the left margin. The first lane is control mouse PRL (3 μg). The sex and genotypes of mice from which each extract was prepared are labeled at the top of each lane. Both wild-type and heterozygous mouse pituitaries contained similar amounts of the full-length immunoreactive PRL. Homozygous mutant mice produced only the predicted truncation product at a molecular weight of~11 kDa. 
An Nb2 cell bioassay was performed on lysates of pituitary glands of individual mice. Each lysate was assayed in duplicate. The minimum detectable level of PRL bioactivity in the assay was 1 pg. a n ϭ number of individual animals in each group.
product; and female heterozygotes, which synthesized higher PRL levels than males, also had a detectable amount of immunoreactive protein which migrated at 11 kDa. Homozygous male and female mice synthesized exclusively the 11 kDa immunoreactive PRL product. The PGK-neo cassette insertion truncated the pre-PRL polypeptide at serine 117 in the second α-helix and added a 12-amino-acid extension (sequence: PRL 117 -TDPPGCRNSIS-stop) before the first stop codon in PGKneo. This results in a 129-amino-acid precursor that would be cleaved to 100 residues by removing the signal peptide. The calculated molecular weight of the polypeptide predicted from the sequence of the targeted gene was 11 306 Da, which corresponds to the 11 kDa immunoreactive band in the PRL -/-mice. Under the conditions of these Western blots, where 10 μg of pituitary extracts were loaded, small amounts of immunoreactive protein migrated faster than the main bands. These smaller products may represent proteolytically cleaved PRL.
Bioassay of pituitary PRL
Pituitary extracts from homozygous wild-type and heterozygous mice had indistinguishable levels of PRL bioactivity (Table I) , The average level of PRL in male mice pituitaries was~12% of that in female mice pituitaries. PRL bioactivity was completely undetectable in pituitaries from both male and female -/-mice. Fertility, maternal behavior and somatic growth of PRL -/-mice Heterozygous crosses yielded the expected ratios of genotypes and genders in the offspring (Table II) . There was no measurable difference in fetal survival of -/-mice and their littermates. Heterozygous females produced normal litter sizes and had no problems with nursing their offspring. Homozygous PRL -/-female mice were completely infertile. Female PRL -/-mice were mated with male mice of known fertility and no litters were produced following more than 15 matings. Each female mated repeatedly at irregular intervals, without entering a state of pseudopregnancy. Estrous cycles of females were assessed by vaginal smear cytology (Champlin, 1973) in six PRL -/-mice. The females all underwent cycles that displayed all of the phases, but the patterns were very irregular. Unlike normal female mice, which have only a single proestrus and a single estrus day in each cycle, the PRL -/-mice had cycles with multiple days of proestus and/or multiple days of estrus. Individual females did not establish any consistent pattern of cycling; subsequent cycles could be either longer or shorter than the normal 4-5 day cycle, with no predictable cycle length for any individual.
Nulliparous female mice (8 weeks old) were tested for maternal behaviors (pup retrieval and crouching) toward foster pups. Four of six ϩ/ϩ females, five of seven ϩ/-females and six of seven -/-females retrieved 2-day-old foster pups and crouched over them in a nursing position within 30 min after placement of the pups in the home cage. Thus, PRL deficiency does not cause any profound defect in the spontaneous maternal behavior exhibited by laboratory mice.
In contrast to the reproductive abnormalities of the female -/-mice, males with the disrupted PRL gene were fully fertile. Matings between -/-male and ϩ/-female mice produced normal litter sizes and normal 1:1 Mendelian gender and genotype ratios (Table III) .
Somatic growth of the mice was not significantly affected by disruption of the PRL gene. Figure 3 shows growth curves for both male and female mice through the first 6 weeks. The -/-mice grew normally, increasing to approximately triple their weight between 2 and 6 weeks of age. There was no significant difference between the body weights of control and targeted mice at any of the ages. In addition to the growth curves done on the young mice, -/-mice were examined at 6 months old, at which age the males averaged 38.9 g and the females averaged 28.6 g. Therefore, PRL deficiency had no discernible effect on growth of the mice at any age.
Gross pathology and histopathology at necropsy
No macroscopic lesion was found in either male or female -/-mice, nor was there any difference at the gross level between control and PRL -/-mice. Of the wide array of tissues examined (see Materials and methods), the only histological abnormality in the 6-week-old -/-mice was a subtle effect in the pituitary glands, where there was a decrease in the volume of the acidophilic cells, consistent with deficient PRL biosynthesis and storage. As there was no bioactive PRL detected in the pituitary glands of -/-mice, pituitary gland function has not yet been studied in any more detail. Further analysis of the pituitary glands will require development of specific N-terminal and C-terminal antibodies that can differentially detect the wild-type and the targeted PRL polypeptides. Histological examination of the mammary glands at 6 weeks of age was equivocal, showing only some modest signs of hyperplasia and neutrophil infiltration in the -/-female mice.
Abnormal mammary gland development in adult virgin PRL -/-mice Mammary gland development includes the formation of a branched ductal system that is decorated with terminal and lateral lobules in virgin adult mice ( Figure 4A ). The growth and differentiation of the mammary gland is under the control of several hormones whose precise roles are still unclear. In PRL -/-mice, terminal end buds form during puberty and the ductal tree grows normally ( Figure  4B ). However, in adult PRL -/-mice, the mammary gland ductal system grows into an extended branching network that is completely devoid of either terminal or lateral lobulation ( Figure 4C ). In normal mice, the differentiation of the ductal system results in a compact glandular structure which undergoes full lobuloalveolar development during pregnancy ( Figure 4D ). In PRL -/-mice, the mammary ducts ended as blunt tubes, or extended tapered tubes, without any lateral or terminal decorations ( Figure  4E and F). Despite the lack of lobulation, there was no compensatory increase in the number of branches formed during the development of the mammary gland.
Effects of PRL on lymphopoiesis
In view of speculation that PRL is a lymphopoietic hormone, B and T cell development was assessed in PRL -/-mice. The data in Figure 5A and 
and CD45R ϩ sIgM ϩ B cells (Fraction E and F) . The data in Figure 6 demonstrate that the frequency of cells in these various B lineage fractions is comparable between the PRL -/-mice and their PRL ϩ/-littermates. As bone marrow cellularity in PRL -/-mice and their PRL ϩ/-littermates was nearly identical (Table IV) , there was no significant difference in the absolute number of B lineage cells in the mice. The analysis of PRL effects on B cell development in Snell dwarf (dw/dw) mice supports the above findings. As previously reported and confirmed in Table V , the frequency of CD45R ϩ B lineage cells in the bone marrow of these mice is significantly depressed when compared with levels present in their ϩ/? littermates (Murphy et al., 
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1992; Montecino-Rodriguez et al., 1996 , 1997 . The data in the table indicate that while treatment of dw/dw mice with 100 μg of ovine PRL/day for 2 weeks resulted in an increase in the number of bone marrow cells, the frequency of CD45R ϩ sIgM -and sIgM ϩ B lineage cells remained depressed. However, as reported previously (MontecinoRodriguez et al., 1996) , B cell defects in the bone marrow of dw/dw mice can be corrected by thyroxine. The potential role of PRL in primary T cell development was determined by comparing the number and frequency of CD4-and/or CD8-expressing thymocytes in PRL -/-mice and their PRL ϩ/-littermates. As shown in Figure  5B and Table VI , the frequencies of CD4 -CD8 -double negative, CD4 ϩ CD8 ϩ double positive and single positive CD4 and CD8 thymocytes were comparable in PRL -/-mice and their PRL ϩ/-littermates. However, although not statistically significant, the average number of cells in the thymus of the PRL ϩ/-mice was lower than in the PRL -/-mice. All values are given as mean Ϯ SD. a n ϭ 5. b n ϭ 9. All values are given as mean Ϯ SD. Lymph node cellularity is given per single lymph node and the phenotypic analysis was carried out on cells pooled from two axillary and two inguinal lymph nodes. a The number of mice in each analysis is given in parentheses.
Cellularity of secondary lymphoid tissues in PRL -/-mice
The data in Table VII demonstrate that spleen and lymph node cellularity and the frequency of IgM-, CD4-, CD8-and CD11b (Mac-1)-expressing cells in PRL -/-mice and their PRL ϩ/-littermates were comparable. The mean number of sIgM ϩ cells was lower in the spleen of PRL -/-mice than in their PRL ϩ/-littermates, although not significantly so.
Myelopoiesis in PRL -/-mice
The expression of the PRL receptor on the majority of hematopoietic cells also raised the possibility that PRL was required for normal development of myeloid cells. Therefore, the frequency of granulocyte-macrophage progenitors responsive to GM-CSF and of CD11b (Mac-1)-expressing cells were enumerated in the PRL -/-mice. The data in Table IV demonstrate that no differences in the frequency of CFU-GM and CD11b (Mac-1) ϩ cells between the PRL -/-mice and their littermates were observed. The hematocrits (51.1 Ϯ 1.5 in PRL -/-and 53.0 Ϯ 0.14 in PRL ϩ/-mice) were similar as well.
Discussion
While PRL has been demonstrated to be required during lactogenesis in the pregnant mammal, its importance in reproductive function in the non-pregnant female has been poorly understood. In addition, there has been speculation that PRL might play a key role in the development of the hematopoietic system. One difficulty in addressing these issues has been the lack of an appropriate animal model for assessing PRL function. There have been three approaches to studying the effects of PRL deficiency in animals: surgical hypophysectomy (Bates et al., 1962) , pharmacological inhibition of PRL secretion (Nagy et al., 1983) and analysis of pituitary dwarf models (Murphy et al., 1992) . None of these approaches has been com-pletely satisfactory, for two reasons. First pituitary ablation does not inactivate potentially important PRL synthesis in extrapituitary tissues and, secondly, many of the changes in these animals might be due to other hormone or drug effects rather than PRL deficiency, per se. To circumvent some of these limitations, we chose to produce a mouse model with an isolated PRL deficiency. The aim of the studies reported herein was to assess the effects of PRL deficiency during postnatal development, with particular emphasis on mammary gland development, reproductive capacity, somatic growth and hematopoiesis. PRL deficiency in these mice was produced by using homologous recombination in embryonic stem cells to interrupt the coding region of the PRL gene with a neomycin-selectable marker. Disrupted PRL synthesis was confirmed by biochemical and biological assays. The mutant mice produced a truncated peptide that reacted with anti-mouse PRL, which was consistent with disruption of the PRL gene by insertion of neo downstream of the bases that encode serine 117. Putative 16K PRL, which has anti-angiogenic properties, is produced by proteolytic cleavage downstream of the third α-helix (residue 174) (Ferrara et al., 1991) . Because the biological properties and receptor for 16K PRL are not well known, it is impossible to infer whether the truncated product in PRL -/-mice might have any activity similar to that proposed for 16K PRL. As the N-terminally truncated fragement is immunoreactive, Western blotting, rather than serum radioimmunoassay, was used to show the deficiency of the protein.
Heterozygous mice produced the full-length PRL protein and bioactive PRL at levels that were identical to homozygous wild-type mice. Therefore, the loss of one PRL locus was compensated for in the mice so that the overall level of PRL synthesis was not reduced. Consistent with this, the heterozygous mice had no difficulties in bearing normal sized litters and nursing their offspring. In contrast, mice heterozygous for a PRL receptor mutation had problems with lactation and nurturing of their first litters because the mammary glands did not reach a full lactational state of differentiation (Ormandy et al., 1997) . This suggests that there is no feedback system to upregulate the PRL receptor in compensation for the loss of one allele, whereas normal levels of PRL can be synthesized from a single allele in the heterozygous mice.
Mice homozygous for the PRL gene mutation were born in normal Mendelian proportions. Similarly, disruption of the PRL receptor gene was also not embryonically lethal (Ormandy et al., 1997) . Despite these similarities, the characteristics of the PRL ligand and receptor knockout mouse strains were not identical. Half of the male receptor -/-mice were infertile or had reduced fertility, whereas the ligand-disrupted male mice were normally fertile. It is possible that reduced fertility in male PRL -/-mice might be revealed if they were challenged with multiple females or were placed in competition with non-mutant males, but these experiments have not been done. PRL receptors are widely distributed in fetal tissues (Freemark et al., 1995) . During the perinatal period, PRL bioactivity may be supplied from the maternal circulation and in the milk (Soares et al., 1991; Kacsóh et al., 1993) . Thus, the PRL -/-mice are probably not absolutely PRL deficient until some time during the nursing period, when maternal proteins are no longer passed to the offspring via the milk. Some differences between PRL ligand-and receptormutant mice may be attributable to the supply of maternal PRL to the offspring. It is also important to consider that PRL is probably hypersecreted in receptor-mutant mice, which may cause non-specific effects during development.
The female PRL -/-mice had irregular estrous cycles and did not become pregnant when mated to stud males. Although PRL is required for maintenance of the corpus luteum in mice, it is not obvious why the estrous cycles of PRL -/-mice should be altered, since there is no functional luteal phase in the estrous cycle of mice, as is present in humans and many other mammals. There were no obvious defects in the ovaries or other genital structures of the PRL -/-mice when examined histologically. PRL receptor knockout mice fail to become pregnant owing to multiple pre-implantation reproductive defects, which result in poor embryo survival and progression (Ormandy et al., 1997) . Similarily, preliminary observations (data not shown) indicate that PRL -/-mice ovulate normal numbers of eggs which can be fertilized but do not progress to implantation. Future experiments will be necessary to address whether the altered cyclicity in PRL -/-mice is caused peripherally (i.e. an ovarian defect) or centrally (i.e. hypothalamic), and whether the fertility defects are similar to those in receptor-null mice. It will be possible to use the PRL -/-mice to determine whether the fertility defects are caused by direct PRL actions on the oviduct and uterus or are secondary to changes in other organs.
Spontaneous maternal behaviors were expressed in PRL -/-mice as well as normal heterozygous and wildtype controls. Unlike some other species, where prior experience is required for the expression of maternal behaviors, naive virgin laboratory mice display a complex suite of maternal behaviors (Noirot, 1969 ). PRL appears not to be required to induce receptivity of naive female mice to foster pups. Disruption of the fosB gene resulted in profoundly defective pup retrieval and crouching behaviors (Brown et al., 1996) ; and preliminary data indicated that PRL levels were normal in the fosB mutant mice. Our results affirm definitively that PRL is not required in order for mice to manifest maternal behaviors. It remains possible that PRL plays some role in maternal behavior in other species, such as rats, where maternal behaviors are dependent on prior experience (Bridges et al., 1985 (Bridges et al., , 1990 .
Postnatal growth of PRL -/-mice was unaltered. Mice grew normally during the first 6 weeks, and the males and females were of normal size at 6 months of age. These results indicate that the PRL mutation did not have any effects on GH or IGF-1 secretion even though GH and PRL are closely related molecules and they are synthesized by cells that can be interconverted (BenJonathan et al., 1996) .
Mammary gland development was altered by PRL deficiency in the virgin adult mice. The ductal system in -/-females grew into an extensively branched, extended network of ducts, with no evidence of terminal or lateral lobular decorations. In contrast, normal mice produced compact mammary gland networks with extensive lobulation. It has been suggested that GH and IGF-1 may be important for both end bud development in early puberty, and differentiation of 'alveolar structures' in the adult (Feldman et al., 1993; Kleinberg, 1997) , which we refer to as 'lobulations' in this paper. Based on our results we can conclude that GH and IGF-1, along with estrogens, may be sufficient to stimulate pubertal growth of terminal end buds. However, PRL is required to drive the subsequent growth and differentiation of the lobular strucures of the adult mouse mammary gland. The terminal end buds of early puberty, which may be stimulated by GH rather than PRL, appear to be physiologically and developmentally different from the lobulations of the adult mouse mammary gland. The end buds of puberty are associated with growth of an extended ductal tree, whereas the lobulations in the adult mammary gland are associated with growth and differentiation of the alveolar structures, which lead to a compact system of glandular tissue.
The disruption of the genes for Stat5a (Liu et al., 1997) and Stat5b (Udy et al., 1997) , as well as the PRL receptor (Ormandy et al., 1997) and ligand (our results) offer some insight into the potential complexity of intracellular signaling mechanisms for PRL. Stat5 was identified as a PRL-stimulated transcription factor in the mammary gland of sheep (Wakao et al., 1994) , and has been associated with mediating PRL actions in a variety of cell types (Gouilleux et al., 1995) . Whereas both the PRL ligandand receptor-null mice showed major defects in fertility and mammary gland development in the females, the Stat5a and Stat5b null mice were each fertile and their mammary glands underwent nearly complete development. Stat5a-deficient mice did not lactate, although the mammary glands developed to a full lobulo alveolar state and synthesized milk proteins (Liu et al., 1997) . This suggests that Stat5a is essential for the full manifestation of lactation, but not for development of the mammary gland or synthesis of milk proteins. Stat5b-deficient mice were fertile and lactated, although the pregnancies of Stat5b-null mice often aborted, and the mice did not produce enough milk to feed their pups (Udy et al., 1997) . In contrast, the PRL receptor (Ormandy et al., 1997 ) and PRL ligand (our studies) are absolutely necessary for fertility of females, and for pre-lactogenic mammary gland development. It is possible that Stat5a and b, or other Stat proteins, have many redundant functions in female reproduction and mammary gland development. If so, disruption of multiple Stat genes would be necessary to cause the reproductive defects seen in PRL-deficient mice. Alternatively, other PRL-activated signal transducers (Horseman et al., 1997) may mediate PRL actions in the female reproductive tract or during some of the prelactational stages of mammary gland development. The availability of mice with disruptions in various genes that have been implicated in PRL action will greatly facilitate studies on the physiological basis of PRL signal transduction.
Maturation of breast tissue in the post-pubertal adult, or during pregnancy, has been associated with a marked reduction in breast cancer risk in both rodents (Welsch and Nagasawa, 1977) and humans (MacMahon et al., 1973) . It has not previously been possible to determine the potential role of PRL in the maturation of breast tissue in the adult because of the inadequacies of the available experimental models. PRL-deficient mice allow us to conclude that PRL is necessary for mammary gland tissue to progress past a pubertal stage of ductal development to an adult state. This indicates that PRL has an important role during the postpubertal maturation of the breast, which may contribute to the refractoriness of breast cells to carcinogenesis. The PRLnull mice will provide an in vivo model in which to examine the relationships between mammary gland development, signal transduction and breast cancers.
A major goal of this study was to determine whether PRL is an obligate hematopoietic hormone in the mouse. No major deficiency in the production of lymphoid or myeloid cells was observed in the PRL -/-mice, strongly suggesting that PRL is not critical for primary, antigen-independent development of lymphoid and myeloid cells. The frequency and absolute number of B lineage cells in the bone marrow of PRL-deficient mice did not differ from values in their normal littermates, and these results were complemented by independent studies performed on dw/dw mice. This strain, which is deficient in growth hormone, PRL and thyroid hormone production, has a well-documented deficiency in the generation of B lineage cells in the bone marrow (Murphy et al., 1992; Montecino-Rodriguez et al., 1996) . While administration of thyroid hormone can restore B lymphopoiesis to normal in this strain (MontecinoRodriguez et al., 1996) , the potential role of PRL has not been reported. Treatment of dw/dw mice with PRL alone, or in combination with growth hormone (data not shown), had no effect on the frequency of bone marrow B lineage cells. These results suggest that PRL is not an important regulator of primary B lymphopoiesis.
Although PRL was not required for B cell development, the number of cells in the bone marrow of PRL-treated dwarf mice was higher than in saline-treated mice. Since PRL has been reported to potentiate the proliferative response of granulocytic and erythroid cells to lineagespecific hematopoietic growth factors (Nagy and Berczi, 1989; Bellone et al., 1995) , the increased bone marrow cellularity may be a consequence of that effect. Nevertheless, while these results suggest the potential of PRL to enhance growth in particular hematopoietic lineages, the presence of a normal hematocrit and normal numbers of myeloid and lymphoid cells in the bone marrow of PRL -/-mice indicates that PRL is not required for normal, steadystate hematopoiesis.
Thymopoiesis also appeared normal in the PRL -/-mice, as the frequency of the thymocyte populations expressing CD4 and/or CD8 was comparable with that in their normal littermates. This observation further suggests that PRL is not an obligate thymopoietic factor. Although not statistically significant, the mean number of cells in the thymus of PRL -/-mice was higher than in their littermates. This observation, together with a report that PRL treatments depress thymocyte cellularity in Snell dwarf mice (Murphy et al., 1993) , raises the possibility that PRL may have an inhibitory effect on cell production in the thymus. However, this conclusion must remain tentative, because an inhibitory effect of PRL on the dwarf mouse thymus was not observed in this (data not shown) or another laboratory (Villanua et al., 1992) , and PRL has no effect on thymic cellularity in normal mice (Murphy et al., 1995) .
Our results also demonstrate that there is a normal distribution of B and T cells in secondary lymphoid organs of PRL -/-mice. This finding does not necessarily imply that PRL has no effect on the secondary responses involving these populations. In fact, there are numerous reports indicating that PRL may modulate the secondary immune response (Gala, 1991; Kelley et al., 1992; Hooghe-Peters and Hooghe, 1995; Murphy et al., 1995) . Additional studies using the PRL -/-mice, as well as the recently described PRL-receptor knockout (Ormandy et al., 1997) , should be of value in delineating the role of PRL in secondary immune responses.
In summary, the data in this report demonstrate that PRL is essential for female reproduction and the post-pubertal differentiation of the mammary gland. The mechanisms involved in PRL actions in the female reproductive tract and in the early differentiation of the mammary gland are not known. In contrast to its essential roles in the female systems, PRL does not appear to be required for normal development of the hematopoietic system. Nevertheless, the expression of the PRL receptor on the majority of developing blood cells provides for the possibility that PRL can have subtle effects on these populations, and it is important to stress that PRL may play a role in modulating secondary immune responses. Future studies will be necessary to assess reproductive defects, secondary immune responses and the neoplastic potential of the mammary gland of PRL -/-mice.
Materials and methods
Generation of PRL mutant mice
A positive-negative selection targeting vector was constructed using the MJK-KO plasmid (Li et al., 1996) kindly provided by Steven Potter (Department of Pediatrics, University of Cincinnati). A region encompassing 5.2 kb of the mouse PRL gene was cloned into MJK-KO such that the PGK-neomycin (neo) selectable marker was inserted into the fourth exon at a unique XhoI site, and the thymidine kinase (tk) negative selection cassette was inserted at a SacI site in intron D (Figure 1) . The neo insertion bisects the PRL gene in the region encoding the second α helix so as to eliminate both sites 1 and 2 of the receptor-binding regions.
Fifty million 129/Sv D3 embryonic stem (ES) cells were electroporated in the presence of 5 nM of NotI linearized targeting vector, and were plated on mitomycin C-treated feeder cells. After 24 h G418 was added at 500 μg/ml and the concentration of G418 was reduced to 20 μg/ml after against tk ϩ cells. Selection of neo r /ganc r cells was completed in 10-14 days. Individual clones were expanded in 24-well culture plates and then screened by PCR. Of 119 clones selected, 28 were confirmed to be targeted by PCR and Southern blotting (Figure 1) . Blastocyst injections and mating of chimeric mice was carried out as described (Shull et al., 1992) . Gene targeting and blastocyst injections were performed in the Gene-Targeted Mouse Core Facility of the University of Cincinnati. Heterozygous F1 pups were identified by PCR and sibling matings were carried out to produce homozygous PRL-deficient mice.
Mouse husbandry and behavior testing PRL -/-mice were maintained in barrier facilities within AAALACaccredited animal quarters under Institutional Animal Care and Use Committee-approved protocols. Snell dwarf (DW/JPit1 dw ) mice (dw/dw) and their ϩ/ϩ and ϩ/-littermates (referred to as ϩ/?) were obtained from the Jackson Laboratories, Bar Harbor, ME. Mice were administered saline, ovine PRL (100 μg/day, lot AFP-10677C; National Hormone and Pituitary Program), or DL-thyroxine (T4; 2 μg/day; Sigma, St Louis, MO) by a single subcutaneous injection daily for 2 weeks.
Retrieval of foster pups and crouching in a nursing posture were assayed to determine whether PRL -/-mice displayed spontaneous maternal behaviors. Three newborn foster pups (2-3 days of age) were placed in the home cage of the nulliparous test females (8 weeks of age) at positions distant from the female and from each other. The mice were observed continuously for 30 min. A positive maternal behavior test was defined as retrieval of all of the foster pups, followed by the female assuming a nursing posture, crouched over the pups (Bridges et al., 1985 (Bridges et al., , 1990 
PRL bioassay
Pituitary PRL content was determined by the Nb2 lymphoma cell bioassay (Gout et al., 1980) as modified by Kascóh (1997) . Briefly, Nb2 cells were growth-arrested by removal of FBS for 24 h. Cells plated in 96-well tissue culture plates were given either PRL standard (NIH sheep PRL-20, 31 IU/mg, gift of the National Hormone and Pituitary Program) or pituitary cell extracts. Individual pituitary glands were suspended in 100 μl PBS and were disrupted by trituration through a micropipette. Cells were lysed by three cycles of freezing and thawing and the lysates were cleared by centrifugation. Protein content was determined by the micro BCA assay according to the manufacturer's protocol (Pierce Chemical Co., Rockford, IL). Cells were incubated with standards and test samples for 48 h and cell proliferation was quantified by MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium) dye conversion. The minimum detectable level of PRL in this assay was 1 pg/well.
Western blotting
Pituitary extracts (10 μg protein/lane) or purified mouse PRL (3 μg, gift of F.Talamantes and L.Ogren, University of California, Santa Cruz) were separated through a 15% (monomer) sodium dodecyl sulfate-polyacrylamide gel. Proteins were electroblotted to nitrocellulose membrane and the transferred proteins were stained with Ponceau S to confirm equivalent loading and transfers. The membrane was blocked by incubation in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.05% Tween-20 and 5% non-fat dried milk. Anti-mouse PRL (gift of F.Talamantes and L.Ogren) was added in the same buffer and incubated with the transferred proteins for 1 h. The membrane was washed twice and incubated for 1 h with goat anti-rabbit IgG-peroxidase conjugate (Sigma Chemical Co., St Louis). After washing three times, the immunoreactive bands were visualized by chemiluminescence using Enhanced Nu-Glo reagent (Alpha Diagnostics, San Antonio) according to the manufacturer's protocol.
Histopathology and morphological analyses
Mice were examined at 6 weeks of age for gross and histological pathologies. The mice were anesthetized and fixed by whole-body formalin perfusion. Organs were examined grossly at necropsy, and were then removed and weighed. The following organs were harvested for examination: eye, conjunctiva, harderian gland, salivary gland, masseter muscle, mandibular lymph node, heart, aorta, renal artery, lung, trachea, thymus, kidney, liver, spleen, stomach, duodenum, jejunum, ileum, ceacum, colon, pancreas, adrenal gland, skin, femur, quadriceps muscle, cranium, cerebrum, cerebellum, mammary gland, vagina, uterus, ovary, testis, epididymis, seminal vesicle, vas deferens, prostate, bulbourethral gland and pituitary gland. Samples of tissues were embedded in paraffin; histological sections were stained with hematoxylin/eosin and examined microscopically by comparing age-matched control and gene-disrupted mouse tissues. For wholemount analyses, the mammary glands were spread on glass microscope slides and fixed with Carnoy's fixative for at least 30 min. The tissues were 6934 washed by incubation in 70% ethanol and defatted with acetone for a minimum of 12 h. They were stained with either iron hematoxylin or safronin O, and photographed at low power under a dissecting microscope or under a 10ϫ objective using an inverted compound microscope. This method was modified from the protocol distributed via the Mammary Gland Biology Internet posting at URL (http://mammary.nih.gov). Morphogenesis of the mammary ducts was compared by counting the number of branches along the primary duct extending along the longest axis of the gland.
Preparation of cell suspensions from hematopoietic organs
Bone marrow cell suspensions were prepared by flushing bones with 3 ml of α-MEM (GIBCO, Grand Island, NY) containing 5% fetal calf serum (Hyclone, Logan, UT). Spleen and thymus cell suspensions were prepared by teasing the organs apart with bent needles or gently pressing them through a fine mesh screen. Cells were counted with a hemacytometer and cell viability, which was always greater than 95%, was determined by eosin dye exclusion. All bone marrow cell counts are expressed as the total number of cells obtained from two femurs and two tibiae.
Immunofluorescence analysis
Expression of particular cell surface determinants was detected by labeling cells with phycoerythrin, fluorescein or biotin-conjugated antibodies to the following cell surface determinants: CD11b (Mac-1; clone M1/70), CD45R (B220; Clone RA3-6B2), CD43 (Clone S7), CD24 (Heat Stable Antigen; clone M1/69). The above antibodies were obtained from Pharmingen, La Jolla, CA. Antibodies to IgM were obtained from Southern Biotechnology, Birmingham, AL. T lineage cells were identified based on labeling with antibodies to CD4 (Clone H129.19) or CD8 (Clone 53-6.7) from Pharmingen. For triple staining, streptavidin conjugated to PerCP (BectonDickinson, San Jose, CA) was used.
Cell suspensions were treated with NH 4 Cl to lyse erythrocytes before staining, and prior to the addition of one or more of the above antibodies, samples were incubated with an antibody to the FcγII and III receptor (CD16/32; clone 2.4G2 from Pharmingen) to reduce non-specific labeling of cells. All staining protocols were conducted in calcium, magnesiumfree phosphate-buffered saline at 4°C. Dead cells were excluded based on their SSC vs. FSC profile or their staining with propidium iodide, added to a final concentration of 0.5 μg/ml per sample. Cell analysis was performed on a Becton-Dickinson FACScan. Gates were set on the basis of staining with either an isotype control antibody conjugated to the same fluorochrome or the secondary reagent alone.
B lineage cells were resolved into various fractions (A-F) based on the technique initially reported by Hardy et al. (1991) . CD45R ϩ CD43 ϩ HSAfraction A cells were distinguished from CD45R ϩ CD43 ϩ HSA ϩ fraction B ϩ C cells on the basis of HSA expression. Fraction D cells were defined as CD45R ϩ CD43 -sIgM -cells.
Myeloid colony assay
Bone marrow cells that formed colonies (CFU-GM) in semisolid medium in response to recombinant granulocyte-macrophage colony stimulating factor were enumerated by plating 5ϫ10 4 cells in 35 mm tissue culture dishes containing 1 ml of methylcellulose medium. This contained 40% of a 0.8% methylcellulose solution, 30% fetal calf serum, 30% Iscoves medium, 5ϫ10 -5 M 2-β-mercaptoethanol and 50 U/ml recombinant GM-CSF (AMGEN, Thousand Oaks, CA). Colonies were counted on day 11.
Statistical analysis
Data were analyzed using a single-tailed Student's t-test. Data are presented as mean Ϯ standard deviation.
